Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/42450
Título: Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
Autores/as: Yabe, Daisuke
Ambos, Anu
Cariou, Bertrand
Duvnjak, Lea
Evans, Marc
González-Gálvez, Guillermo
Lin, Jay
Nikonova, Elena V.
De Pablos-Velasco, Pedro 
Yale, Jean-François
Ahrén, Bo
Clasificación UNESCO: 320502 Endocrinología
32 Ciencias médicas
Palabras clave: Antidiabetic drug
Beta cell
GLP-1 analog
Glycemic control
Type 2 diabetes
Fecha de publicación: 2016
Publicación seriada: Journal of Diabetes and its Complications 
Resumen: Aims To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20 μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), − 0.99 (− 10.8), − 0.87 (− 9.5), − 0.86 (− 9.4), − 0.83 (− 9.1); and postprandial plasma glucose (PPG; mmol/L), − 7.9, − 5.6, − 5.5, − 4.3 (overall effect P < 0.0001). Furthermore, postprandial glucagon was reduced in all SUIT quartiles, while insulinogenic index improved only in patients with higher baseline SUIT (overall effect P = 0.0286). No severe symptomatic hypoglycemic events were reported. Conclusions Lixisenatide treatment resulted in reductions in HbA1c and PPG levels across all SUIT quartiles. This suggests that non-insulin-related actions of lixisenatide contribute to improved glycemic control in T2D.
URI: http://hdl.handle.net/10553/42450
ISSN: 1056-8727
DOI: 10.1016/j.jdiacomp.2016.05.018
Fuente: Journal of Diabetes and its Complications [ISSN 1056-8727], v. 30 (7), p. 1385-1392
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.